Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554037 | 0.92 | MAPT (0.40) | NPC1RAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2134704 | 0.91 | CDK5 (0.41) | CDK5CDK5R1NAMPTKMT2A | |
| SCHEMBL2131025 | 0.89 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL2135642 | 0.89 | TGFBR1 (0.37) | CDK5CDK5R1 | |
| SCHEMBL1506075 | 0.87 | NPC1 (0.42) | NPC1RAB9A | |
| SCHEMBL2132961 | 0.86 | CDK5 (0.36) | NPC1RAB9ASMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL2132617 | 0.86 | CYP19A1 (0.41) | CDK5CDK5R1 | |
| SCHEMBL2133723 | 0.85 | MAPK1 (0.38) | — | |
| SCHEMBL1505684 | 0.84 | PKM (0.38) | CDK5CDK5R1NAMPT | |
| SCHEMBL1553153 | 0.84 | KDM4E (0.36) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| EP-2262801-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | NPC1 1917/4885RAB9A 2690/4885SMN1; SMN2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.